World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
25354
World Ranking
17946
National Ranking
1639

Overview

David I. Marks is affiliated with the University Hospitals Bristol NHS Foundation Trust in the United Kingdom. Their research primarily focuses on the medical field with a significant emphasis on hematology, public health, oncology, genetics, and pediatrics.

Their scholarly output includes a range of publications in influential journals and venues, demonstrating a focus on various hematological and oncological conditions. Frequent publication venues for their work include:

  • Blood
  • UNC Libraries
  • Blood Advances
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology

Main topics covered in their research are diverse within hematology and oncology, with particular attention to:

  • Acute Lymphoblastic Leukemia research
  • Hematopoietic Stem Cell Transplantation
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • CAR-T cell therapy research
  • Childhood Cancer Survivors' Quality of Life
  • Chronic Lymphocytic Leukemia Research

Notable recent papers authored or co-authored by David I. Marks include:

  • Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy, 2020, Biology of Blood and Marrow Transplantation
  • Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL, 2021, Blood
  • Survival following allogeneic transplant in patients with myelofibrosis, 2020, Blood Advances
  • Management of ALL in adults: 2024 ELN recommendations from a European expert panel, 2024, Blood
  • Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia, 2021, Blood Advances

David I. Marks collaborates frequently with several researchers, reflecting active engagement in the scientific community. Their frequent co-authors include:

  • Wael Saber
  • Hillard M. Lazarus
  • Bipin N. Savani
  • Mahmoud Aljurf
  • Taiga Nishihori

Best Publications

  • Outcomes after transplantation of cord Blood or bone marrow from unrelated donors in adults with leukemia

    Mary J. Laughlin;Mary Eapen;Pablo Rubinstein;John E. Wagner

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.

    Antonio Galleu;Yanira Riffo-Vasquez;Cristina Trento;Cara Lomas

  • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis

    Mary Eapen;Vanderson Rocha;Guillermo Sanz;Andromachi Scaradavou

  • Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

    Brian L. McClune;Daniel J. Weisdorf;Tanya L. Pedersen;Gisela Tunes da Silva

  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure

    Michel Duval;John P. Klein;Wensheng He;Jean Yves Cahn

  • Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis

    Pierre Teira;Minoo Battiwalla;Muthalagu Ramanathan;A. John Barrett

  • Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

    Navneet S. Majhail;Stephanie H. Farnia;Paul A. Carpenter;Richard E. Champlin

  • Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

    Koen Van Besien;Fausto R. Loberiza;Ruta Bajorunaite;James O. Armitage

  • T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).

    David I. Marks;Elisabeth M. Paietta;Anthony V. Moorman;Susan M. Richards

  • UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

    Adele K. Fielding;Jacob M. Rowe;Georgina Buck;Letizia Foroni

  • Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

    Robert J. Soiffer;Jennifer LeRademacher;Vincent Ho;Fangyu Kan

  • Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ECOG2993

    Adele K. Fielding;Jacob M. Rowe;Susan M. Richards;Georgina Buck

  • OUTCOME OF TRANSPLANTATION FOR MYELOFIBROSIS

    Karen K. Ballen;Smriti Shrestha;Kathleen A. Sobocinski;Mei Jie Zhang

  • Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.

    Jorge Sierra;Waleska S. Pérez;Ciril Rozman;Enric Carreras

  • Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation

    A. Baldwin;H. Kingman;M. Darville;A. B. M. Foot

  • Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation

    David I Marks;Antonio Pagliuca;Christopher C Kibbler;Axel Glasmacher

  • Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

    M. Eapen;S. A. Giralt;M. M. Horowitz;J. P. Klein

  • The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

    David I Marks;Richard Lush;Jamie Cavenagh;Donald W Milligan

Frequent Co-Authors

Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Bipin N. Savani
Bipin N. Savani Vanderbilt University Medical Center
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Daniel J. Weisdorf
Daniel J. Weisdorf University of Minnesota
Mahmoud Aljurf
Mahmoud Aljurf King Faisal Specialist Hospital & Research Centre
Martin S. Tallman
Martin S. Tallman Northwestern University
Mei-Jie Zhang
Mei-Jie Zhang Medical College of Wisconsin
Nigel H. Russell
Nigel H. Russell University of Nottingham
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in Medicine doesn’t always mean following a traditional MD path. There are a variety of online degrees and alternative career pathways in the healthcare sector that offer competitive salaries, job stability, and meaningful work.

If you’re interested in the business and administrative side of healthcare, pursuing health administration degrees online can open doors to leadership roles in hospitals and clinics. For those seeking advanced opportunities, several online mha programs affordable exist, combining flexibility with cost-effectiveness.

Nursing professionals might be interested in moving up the clinical ladder with a DNP. The best online bsn to dnp programs allow registered nurses to become advanced practice leaders while working and studying remotely. Alternatively, aspiring pharmacists can reduce education costs by exploring online pharmacy school cost comparisons to find affordable, accredited PharmD programs.

These online degrees can offer more flexible and cost-effective options for ambitious students aiming to make a difference in healthcare—without always taking the traditional medical school path.

Best Scientists Citing David I. Marks

Trending Scientists

Recently Published Articles